GenMark Diagnostics (GNMK) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GenMark Diagnostics Reports Q2 Financial Results
August 6, 2015 4:05 PM EDTSecond Quarter Revenue of $7.6 Million, Up 17% Versus Prior Year
XT-8 Installed Base Expanded by 29 to 591
European ePlex Launch Expected by the End of Fourth Quarter 2015
Full Year Revenue Guidance Maintained at $38-40 Million; Gross Margin Increased to 57-59%
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported second quarter 2015 financial results.
Revenue for the second quarter of 2015 was $7.6 million,... More
